Above all, we make a difference.
Home > Breast Cancer Information > Treatment > Treatment References

Treatment References

  1. Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 13(4):412-9, 2012.
  2. De la Cruz Ku G, Karamchandani M, Chambergo-Michilot D, et al. Does breast-conserving surgery with radiotherapy have a better survival than mastectomy? A meta-analysis of more than 1,500,000 patients. Ann Surg Oncol. 29(10):6163-6188, 2022.
  3. Darby S, McGale P, Correa C, et al. for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 378(9804):1707-16, 2011.
  4. Arthur DW, Winter KA, Kuerer HM, et al. Effectiveness of breast-conserving surgery and 3-dimensional conformal partial breast reirradiation for recurrence of breast cancer in the ipsilateral breast: the NRG Oncology/RTOG 1014 phase 2 clinical trial. JAMA Oncol. 6(1):75-82, 2020.
  5. Mehrara B. Breast cancer-associated lymphedema. In: UpToDate (Hayes DF, Nekhlyudov L, Bruera E, Ganz PA, Collins KA and Vora SR, eds.). Waltham, MA: UpToDate, 2023.
  6. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Survivorship. V.1.2023. http://www.nccn.org, 2023.
  7. Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. 265(3):581-589, 2017.
  8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment—breast, ovarian and pancreatic cancer. Version 1.2024. http://www.nccn.org, 2024.
  9. Patrick JL, Hasse ME, Feinglass J, Khan SA. Trends in adherence to NCCN guidelines for breast conserving therapy in women with Stage I and II breast cancer: Analysis of the 1998-2008 National Cancer Data Base. Surg Oncol. 26(4):359-367, 2017.
  10. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer V.5.2023. http://www.nccn.org/, 2023.
  11. Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without Irradiation in early breast cancer. N Engl J Med. 388(7):585-594, 2023.
  12. National Cancer Institute. Radiation therapy and you: support for people with cancer. https://www.cancer.gov/publications/patient-education/radiation-and-you-2021-508.pdf, 2021.
  13. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Cancer-related fatigue. V.2.2023. http://www.nccn.org/, 2023.
  14. Escalante CP. Cancer-related fatigue: treatment. In: UpToDate (Hesketh PJ, Ganz PA, Vora S, eds.). Waltham, MA: UpToDate, 2023.
  15. Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 9:CD005001, 2016.
  16. Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 3(7):961-968, 2017.
  17. Naoum GE, Roberts S, Brunelle CL, et al. Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control: long-term results from a prospective screening trial. J Clin Oncol. 38(29):3430-3438, 2020.
  18. Taylor C, Correa C, Duane FK, et al. for the Early Breast Cancer Trialists’ Collaborative Group. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 35(15):1641-1649, 2017.
  19. Veiga LHS, Vo JB, Curtis RE, et al. Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol. 23(11):1451-1464, 2022.
  20. Wiener AA, Schumacher JR, Hanlon B, Anderson B, Neuman HB. Incidence of radiation-associated sarcoma after breast-conserving surgery plus radiation. J Surg Oncol. 127(4):535-540, 2023.
  21. Whelan TJ, Smith S, Parpia S, et al. for the LUMINA Study Investigators. Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer. N Engl J Med. 389(7):612-619, 2023.
  22. Poppe MM, Yehia ZA, Baker C, et al. 5-year update of a multi-institution, prospective phase 2 hypofractionated postmastectomy radiation therapy trial. Int J Radiat Oncol Biol Phys. 107(4):694-700, 2020.
  23. Brunt AM, Haviland JS, Wheatley DA, et al. for the FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 395(10237):1613-1626, 2020.
  24. Mutter RW, Giri S, Fruth BF, et al. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial. Lancet Oncol. 24(10):1083-1093, 2023.
  25. Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 317(6):606-614, 2017.
  26. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA. 317(6):596-605, 2017.
  27. Munzone E, Bagnardi V, Campennì G, et al. Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines. Br J Cancer. 121(4):325-331, 2019.
  28. Villarreal-Garza C, Mesa-Chavez F, Garza-Ledezma MRA, et al. Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention. Breast Cancer Res Treat. 185(2):453-458, 2021.
  29. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press, 2017.
  30. Azizoddin DR, Cohn AM, Ulahannan SV, et al. Cannabis use among adults undergoing cancer treatment. Cancer. 129(21):3498-3508.
  31. American Cancer Society. Diarrhea. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/stool-or-urine-changes/diarrhea.html, 2020.
  32. Krishnamurthi SS and Macaron C. Management of acute chemotherapy-related diarrhea. In: UpToDate (Drews RE and Vora SR, eds.). Waltham, MA: UpToDate, 2023.
  33. Ruddy KJ and Ginsburg ES. Chapter 90: Reproductive issues in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  34. Stan D, Hershman D, Loprinzi CL. Chapter 51: Management of menopausal symptoms in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  35. Saquib N, Flatt SW, Natarajan L, et al. Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study. Breast Cancer Res Treat. 105(2):177-86, 2007.
  36. Nyrop KA, Deal AM, Shachar SS, et al. Weight trajectories in women receiving systemic adjuvant therapy for breast cancer. Breast Cancer Res Treat. 179(3):707-720, 2020.
  37. Qin B, Kim K, Goldman N, et al. Multilevel factors for adiposity change in a population-based prospective study of black breast cancer survivors. J Clin Oncol. 40(20):2213-2223, 2022.
  38. Manneville F, Rotonda C, Conroy T, Bonnetain F, Guillemin F, Omorou AY. The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer. Cancer. 124(4):797-806, 2018.
  39. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 123(3):627-35, 2010.
  40. Ewertz M, Jensen MB, Gunnarsdóttir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 29(1):25-31, 2011.
  41. Jeon YW, Kang SH, Park MH, Lim W, Cho SH, Suh YJ. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. BMC Cancer. 15:865, 2015.
  42. Cecchini R, Swain SM, Costantino JP, et al. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiol Biomarkers Prev. 25(1):51-9, 2016.
  43. Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 30(29):3578-87, 2012.
  44. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 30(30):3675-86, 2012.
  45. Mandelblatt JS, Clapp JD, Luta G, et al. Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer. 122(22): 3555–3563, 2016.
  46. Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 35(5): 506–514, 2017.
  47. Mandelblatt JS, Zhai W, Ahn J, et al. Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study. Cancer. 126(6):1183-1192, 2020.
  48. Wagner LI, Gray RJ, Sparano JA, et al. Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results From TAILORx. J Clin Oncol. 38(17):1875-1886, 2020.
  49. Hermelink K, Bühner M, Sckopke P, et al. Chemotherapy and post-traumatic stress in the causation of cognitive dysfunction in breast cancer patients. J Natl Cancer Inst. 109(10):djx057, 2017.
  50. Bluethmann SM, Alfano CM, Clapp JD, et al. Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). Breast Cancer Res Treat. 165(3):677-86, 2017.
  51. Jebahi F, Sharma S, Bloss JE, Wright HH. Effects of tamoxifen on cognition and language in women with breast cancer: A systematic search and a scoping review. Psychooncology. 30(8):1262-1277, 2021.
  52. Lee Meeuw Kjoe PR, Kieffer JM, Small BJ, et al. Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer. JNCI Cancer Spectr. 7(2):pkad022, 2023.
  53. Gutenkunst SL, Vardy JL, Dhillon HM, Bell ML. Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems. Support Care Cancer. 29(3):1377-1386, 2021.
  54. Lange M, Arbogast SL, Hardy-Léger I, et al. Cognitive change in breast cancer patients up to 2 years after diagnosis. J Natl Cancer Inst. 115(3):322-331, 2023.
  55. Dijkshoorn ABC, van Stralen HE, Sloots M, et al. Prevalence of cognitive impairment and change in patients with breast cancer: A systematic review of longitudinal studies. Psychooncology. 30(5):635-648, 2021.
  56. Rentscher KE, Bethea TN, Zhai W, et al. Epigenetic aging in older breast cancer survivors and noncancer controls: preliminary findings from the Thinking and Living with Cancer Study. Cancer. 129(17):2741-2753, 2023.
  57. Mandelblatt JS, Small BJ, Luta G, et al. Cancer-related cognitive outcomes among older breast cancer survivors in the Thinking and Living With Cancer Study. J Clin Oncol. 36(32):3211-3222, 2018.
  58. National Cancer Institute. Memory or concentration problems and cancer treatment. https://www.cancer.gov/about-cancer/treatment/side-effects/memory, 2023.
  59. Azim HA Jr, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 22(9):1939-47, 2011.
  60. Dent SF, Botros J, Rushton M, et al. Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience. Breast Cancer Res Treat. 184(3):733-741, 2020.
  61. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 32(20):2159-65, 2014.
  62. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 34(6):581-7, 2016.
  63. Greenlee H, Iribarren C, Rana JS, et al. Risk of cardiovascular disease in women with and without breast cancer: the Pathways Heart Study. J Clin Oncol. 40(15):1647-1658, 2022.
  64. Wolff AC, Blackford AL, Visvanathan K, et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the National Comprehensive Cancer Network experience. J Clin Oncol. 33(4):340-8, 2015.
  65. Jabagi MJ, Vey N, Goncalves A, Tri TL, Zureik M, Dray-Spira R. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. Int J Cancer. 148(2):375-384, 2021.
  66. Freedman RA, Seisler DK, Foster JC, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat. 161(2):363-373, 2017.
  67. Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez-MacGregor M. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. Cancer. 124(5):899-906, 2018.
  68. American Cancer Society. Peripheral neuropathy. https://www.cancer.org/cancer/managing-cancer/side-effects/pain/peripheral-neuropathy.html, 2024.
  69. O’Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 17(34):4665-4676, 2021.
  70. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361(2):123-34, 2009.
  71. Tung NM, Robson ME, Ventz S. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 38(36):4274-4282, 2020.
  72. Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 38(5):388-394, 2020.
  73. Villacampa G, Falato C, Paré L, et al. Pre-operative ribociclib plus letrozole versus chemotherapy: health-related quality of life outcomes from the SOLTI CORALLEEN trial. Eur J Cancer. 174:232-242, 2022.
  74. Coleman R, Powles T, Paterson A, et al. for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 386(10001):1353-61, 2015.
  75. Eisen A, Somerfield MR, Accordino MK, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol. 40(7):787-800, 2022.
  76. Gnant M, Pfeiler G, Steger GG, et al. for the Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20(3):339-351, 2019.
  77. Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 21(1):60-72, 2020.
  78. Saura C, Hlauschek D, Oliveira M, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 20(9):1226-1238, 2019.
  79. Loibl S, Schneeweiss A, Huober J, et al. for GBG and AGO-B. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 33(11):1149-1158, 2022.
  80. Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 110(6):560-567, 2018.
  81. Sparano J, O’Neill A, Alpaugh K, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4(12):1700-1706, 2018.
  82. Trapp E, Janni W, Schindlbeck C, et al. for the SUCCESS Study Group. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst. 111(4):380-387, 2019.
  83. Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 5(10):1473-1478, 2019.
  84. Radovich M, Jiang G, Hancock BA, et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol. 6(9):1410-1415, 2020.
  85. Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 40(16):1816-1837, 2022.
  86. Haque R, Shi J, Schottinger JE, et al. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst. 108(3):djv337, 2015.
  87. Regan MM, Leyland-Jones B, Bouzyk M, et al. on behalf of the Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst. 104(6):441-451, 2012.
  88. Rae JM, Drury S, Hayes DF, et al. on behalf of the ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 104(6):452-460, 2012.
  89. Davies C, Godwin J, Gray R, et al. for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378(9793):771-84, 2011.
  90. Dowsett M, Forbes JF, Bradley R, et al. for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 386(10001):1341-52, 2015.
  91. Kramer I, Schaapveld M, Oldenburg HSA, et al. The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype. J Natl Cancer Inst. 111(7):djz010, 2019.
  92. Pagani O, Walley BA, Fleming GF, et al. for the SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-op of the combined TEXT and SOFT trials. J Clin Oncol. 41(7):1376-1382, 2023.
  93. Baek SY, Noh WC, Ahn SH, et al. Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial. J Clin Oncol. 41(31):4864-4871, 2023.
  94. U.S. Food and Drug Administration. Menopause and hormones: Common questions. https://www.fda.gov/media/130242/download, 2019.
  95. Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat. 136(2):495-502, 2012.
  96. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 108(7):1515-24, 2013.
  97. Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. 34(21):2452-9, 2016.
  98. Ekholm M, Bendahl PO, Fernö M, et al. for the South Swedish and South-East Swedish Breast Cancer Groups. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial. Eur J Cancer. 110:53-61, 2019.
  99. Dar H, Johansson A, Nordenskjöld A, et al. Assessment of 25-year survival of women with estrogen receptor-positive/ERBB2-negative breast cancer treated with and without tamoxifen therapy: a secondary analysis of data From the Stockholm tamoxifen randomized clinical Trial. JAMA Netw Open. 4(6):e2114904, 2021.
  100. Johansson A, Dar H, van ‘t Veer LJ, et al. Twenty-year benefit from adjuvant goserelin and tamoxifen in premenopausal patients with breast cancer in a controlled randomized clinical trial. J Clin Oncol. 40(35):4071-4082, 2022.
  101. Davies C, Pan H, Godwin J, et al. for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 381(9869):805-16, 2013.
  102. Vogel VG, Costantino JP, Wickerham DL, et al. for the National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res. 3(6):696-706, 2010.
  103. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 326(13):852-6, 1992.
  104. Vehmanen L, Saarto T, Blomqvist C, et al. Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. Br J Cancer 91(3):476-81, 2004.
  105. Rimawi MF and Osborne CK. Chapter 43: Adjuvant systemic therapy: endocrine therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  106. Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 24(6):1434-43, 2013.
  107. Eggemann H, Bernreiter AL, Reinisch M, et al. Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. Br J Cancer. 120(3):301-305, 2019.
  108. Cuzick J, Sestak I, Baum M, et al. for the ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11(12):1135-41, 2010.
  109. Morden JP, Alvarez I, Bertelli G, et al. Long-term follow-up of the Intergroup Exemestane Study. J Clin Oncol. 35(22):2507-2514, 2017.
  110. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 37(5):423-438, 2019.
  111. Ruhstaller T, Giobbie-Hurder A, Colleoni M, et al. for the members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 37(2):105-114, 2019.
  112. Goss PE, Ingle JN, Pritchard KI, et al. Aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 375(3):209-19, 2016.
  113. Iwase T, Saji S, Iijima K, et al. Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial. J Clin Oncol. 41(18):3329-3338, 2023.
  114. Mamounas EP, Bandos H, Rastogi P, et al. Ten-year update: NRG Oncology/NSABP B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 115(11):1302-1309, 2023.
  115. De Placido S, Gallo C, De Laurentiis M, et al. for the GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol. 19(4):474-485, 2018.
  116. Goldvaser H, Barnes TA, Šeruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 110(1): djx141, 2018.
  117. Gnant M, Fitzal F, Rinnerthaler G, et al. for the Austrian Breast and Colorectal Cancer Study Group. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med. 385(5):395-405, 2021.
  118. Goss PE, Ingle JN, Alés-Martínez JE, et al. for the NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 364(25):2381-91, 2011.
  119. Cuzick J, Sestak I, Forbes JF, et al. on behalf of the IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 383(9922):1041-8, 2014.
  120. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 103(17):1299-309, 2011.
  121. Beckwée D, Leysen L, Meuwis K, Adriaenssens N. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer. 25(5):1673-1686, 2017.
  122. Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J. Anastrozole-induced carpal tunnel syndrome: results from the International Breast Cancer Intervention Study II Prevention Trial. J Clin Oncol. 34(2):139-43, 2016.
  123. Chung KY, Ho G, Novak CB, Baltzer HL. Aromatase inhibitor-induced carpal tunnel syndrome and stenosing tenosynovitis: a systematic review. Plast Reconstr Surg. 149(3):445e-452e, 2022.
  124. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 33(10):1104-11, 2015.
  125. Hershman DL, Unger JM, Greenlee H, et al. Comparison of acupuncture vs sham acupuncture or waiting list control in the treatment of aromatase inhibitor-related joint pain: a randomized clinical trial. JAMA Netw Open. 5(11):e2241720, 2022.
  126. Mao JJ, Ismalia N, Bao T, et al. Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 40:3998-4024, 2022.
  127. Baglia ML, Lin IH, Cartmel B, et al. Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors. Cancer. 125(13):2262-2271, 2019.
  128. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28(35):5132-9, 2010.
  129. Rathbone EJ, Brown JE, Marshall HC, et al. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol. 31(21):2685-91, 2013.
  130. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Exercise for your bone health. https://www.bones.nih.gov/health-info/bone/bone-health/exercise/exercise-your-bone-health, 2023.
  131. Harris SR, Schmitz KH, Campbell KL, McNeely ML. Clinical practice guidelines for breast cancer rehabilitation: syntheses of guideline recommendations and qualitative appraisals. Cancer. 118(8 Suppl):2312-24, 2012.
  132. National Institute of Arthritis and Musculoskeletal and Skin Diseases. The Surgeon General’s Report on Bone Health and Osteoporosis: What It means to you. https://www.niams.nih.gov/health-topics/surgeon-generals-report-bone-health-and-osteoporosis-what-it-means-you, 2023.
  133. Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 32(35):3948-58, 2014.
  134. Bui KT, Willson ML, Goel S, Beith J, Goodwin A. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst Rev. 3(3):CD013538, 2020.
  135. Francis PA, Fleming GF, Láng I, et al. for the SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation). Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 41(7):1370-1375, 2023.
  136. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 23(3):382-392, 2022.
  137. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical practice guideline update on ovarian suppression. J Clin Oncol. 34(14):1689-701, 2016.
  138. Baek SY, Noh WC, Ahn SH, et al. Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial. J Clin Oncol. 41(31):4864-4871, 2023.
  139. U.S. Food and Drug Administration (FDA). Verzenio labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208716s006s007s008lbl.pdf, 2021.
  140. Rastogi P, O’Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 42(9):987-993, 2024.
  141. Villacampa G, Falato C, Paré L, et al. Pre-operative ribociclib plus letrozole versus chemotherapy: health-related quality of life outcomes from the SOLTI CORALLEEN trial. Eur J Cancer. 174:232-242, 2022.
  142. Rakha EA, Pinder SE, Bartlett JM, et al. for the National Coordinating Committee for Breast Pathology. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol. 68(2):93-9, 2015.
  143. Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer. In: UpToDate. Burstein H, Vora SR (eds.). Waltham, MA: UpToDate, 2023.
  144. Slamon D, Eiermann W, Robert N, et al. for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365(14):1273-83, 2011.
  145. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 32(33):3744-52, 2014.
  146. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. for the Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017 Mar 25;389(10075):1195-1205, 2017.
  147. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 34(6):581-7, 2016.
  148. von Minckwitz G, Huang CS, Mano MS, et al. for the KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 380(7):617-628, 2019.
  149. Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. J Clin Oncol. 37(25):2206-2216, 2019.
  150. U.S. Food and Drug Administration (FDA). Kadcyla labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf, 2019.
  151. von Minckwitz G, Procter M, de Azambuja E, et al. for the APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 377(2):122-131, 2017.
  152. U.S. Food and Drug Administration (FDA). Perjeta labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf, 2020.
  153. Martin M, Holmes FA, Ejlertsen B, et al. for the ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18(12):1688-1700, 2017.
  154. U.S. Food and Drug Administration (FDA). Nerlynx labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf, 2021.
  155. Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 6(5):676-684, 2020.
  156. Schmid P, Cortes J, Dent R, et al. for the KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 386(6):556-567, 2022.
  157. U.S. Food and Drug Administration (FDA). Keytruda labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf, 2022.
  158. Tutt ANJ, Garber JE, Kaufman B, et al. for the OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 384(25):2394-2405, 2021.
  159. American Society of Clinical Oncology (ASCO). Management of hereditary breast cancer: Rapid recommendation update. https://www.asco.org/research-guidelines/quality-guidelines/guidelines/breast-cancer?intcmp=ws_ascoorg_gdlns_hereditarybreastcancer_site_pressrelease_061621____#/143725, 2021.
  160. Geyer Jr CE, Garber JE, Gelber RD, et al. for the OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 33(12):1250-1268, 2022.
  161. U.S. Food and Drug Administration (FDA). Lynparza (olaparib) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf, 2022.
  162. Fasching PA, Link T, Hauke J, et al. for the German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 32(1):49-57, 2021.
  163. Chen Y, Shi XE, Tian JH, Yang XJ, Wang YF, Yang KH. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis. Medicine (Baltimore). 97(20):e10634, 2018.
  164. Li XB, Krishnamurti U, Bhattarai S, et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 145(6):871-8, 2016.
  165. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 35(18):2062-2081, 2017.
  166. U.S. Food and Drug Administration. Biosimilar basics for patients. https://www.fda.gov/drugs/biosimilars/basics-patients, 2023.
  167. Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 67(4):290-303, 2017.
  168. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – SEER 5-year relative survival rates, 2014-2020, by stage at diagnosis, female, all races/ethnicities, all ages. Accessed on May 6, 2024. https://seer.cancer.gov/explorer/, 2024.
  169. Carlson RW. Chapter 67: Surveillance of patients following primary therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  170. Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol. 34(9):927-35, 2016.
  171. Harris JR and Morrow M. Chapter 35: Breast-conserving surgery, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  172. Braunstein LZ, Taghian AG, Niemierko A, et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat. 161(1):173-179, 2017.
  173. Sabel MS, Hirsch A, Bellon JR. Clinical manifestations and evaluation of locoregional recurrences of breast cancer. In: UpToDate (Hayes DF, Chagpar AB, Chen W, Vora SR, eds.). Waltham, MA: UpToDate, 2023.
  174. National Cancer Institute. Inflammatory breast cancer. http://www.cancer.gov/types/breast/ibc-fact-sheet, 2016.
  175. Taghian A and Merajver SD. Inflammatory breast cancer: Clinical features and treatment. In: UpToDate (Hayes DF, Pierce LJ, Chagpar AB, Vora SR, eds.). Waltham, MA: UpToDate, 2024.
  176. Schairer C, Li Y, Frawley P, et al. Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst. 105(18):1373-84, 2013.
  177. Atkinson RL, El-Zein R, Valero V, et al. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 27(3):359-66, 2016.
  178. Abraham HG, Xia Y, Mukherjee B, Merajver SD. Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. Breast Cancer Res Treat. 185(1):229-238, 2021.
  179. Tsai CJ, Li J, Gonzalez-Angulo AM, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol. 38(3):242-7, 2015.
  180. van Uden DJ, Bretveld R, Siesling S, de Wilt JH, Blanken-Peeters CF. Inflammatory breast cancer in the Netherlands; improved survival over the last decades. Breast Cancer Res Treat. 162(2):365-374, 2017.
  181. Kupstas AR, Hoskin TL, Day CN, Boughey J C, Habermann EB, Hieken TJ. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. Br J Surg. 107(8):1033-1041, 2020.
  182. Grova MM, Strassle PD, Navajas EE, et al. The prognostic value of axillary staging following neoadjuvant chemotherapy in inflammatory breast cancer. Ann Surg Oncol. 28(4):2182-2190, 2021.
  183. Adesoye T, Everidge S, Chen J, et al. Low rates of local-regional recurrence among inflammatory breast cancer patients after contemporary trimodal therapy. Ann Surg Oncol. 30(10):6232-6240, 2023.
  184. Moffat FL. Chapter 28: Clinical and pathologic prognostic and predictive factors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  185. Mehrara BJ and Ho AY. Chapter 36: Breast reconstruction, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  186. Fischer JP, Nelson JA, Kovach SJ, Serletti JM, Wu LC, Kanchwala S. Impact of obesity on outcomes in breast reconstruction: analysis of 15,937 patients from the ACS-NSQIP datasets. J Am Coll Surg. 217(4):656-64, 2013.
  187. Matsen CB, Mehrara B, Eaton A, et al. Skin flap necrosis after mastectomy with reconstruction: a prospective study. Ann Surg Oncol. 23(1):257-64, 2016.
  188. Panayi AC, Agha RA, Sieber BA, Orgill DP. Impact of obesity on outcomes in breast reconstruction: a systematic review and meta-analysis. J Reconstr Microsurg. 34(5):363-375, 2018.
  189. Roy M, Sebastiampillai S, Zhong T, Hofer SOP, O’Neill AC. Synergistic interaction increases complication rates following microvascular breast reconstruction. Plast Reconstr Surg. 144(1):1e-8e, 2019.
  190. Zhong T, Hu J, Bagher S, et al. Decision regret following breast reconstruction: the role of self-efficacy and satisfaction with information in the preoperative period. Plast Reconstr Surg. 132(5):724e-734e, 2013.
  191. Cai L, Momeni A. The impact of reconstructive modality and postoperative complications on decision regret and patient-reported outcomes following breast reconstruction. Aesthetic Plast Surg. 46(2):655-660, 2022.
  192. Kuhlefelt C, Homsy P, Repo JP, Jahkola T, Kauhanen S. Health-related quality of life after breast reconstruction: comparing outcomes between reconstruction techniques using the BREAST-Q. World J Surg. 46(11):2695-2705, 2022.
  193. Lee GK, Sheckter CC. Breast reconstruction following breast cancer treatment-2018. JAMA. 320(12):1277-1278, 2018.
  194. Bennett KG, Qi J, Kim HM, Hamill JB, Pusic AL, Wilkins EG. Comparison of 2-year complication rates among common techniques for postmastectomy breast reconstruction. JAMA Surg. 153(10):901-908, 2018.
  195. U.S. Food and Drug Administration (FDA). Risks and complications of breast implants. https://www.fda.gov/medical-devices/breast-implants/risks-and-complications-breast-implants, 2023.
  196. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med. 342(11):781-90, 2000.
  197. Singh N, Picha GJ, Hardas B, Schumacher A, Murphy DK. Five-year safety data for more than 55,000 subjects following breast implantation: comparison of rare adverse event rates with silicone implants versus national norms and saline implants. Plast Reconstr Surg. 140(4):666-679, 2017.
  198. Leberfinger AN, Behar BJ, Williams NC, et al. Breast implant-associated anaplastic large cell lymphoma: a systematic review. JAMA Surg. 152(12):1161-1168, 2017.
  199. de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 4(3):335-341, 2018.
  200. U.S. Food and Drug Administration. Questions and answers about breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). https://www.fda.gov/medical-devices/breast-implants/questions-and-answers-about-breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl, 2019.
  201. Mehta-Shah N, Ghione P. An updated approach and understanding of breast implant-associated anaplastic large cell lymphoma. J Natl Compr Canc Netw. 20(3):309-315, 2022.
  202. U.S. Food and Drug Administration. Medical device reports of breast implant-associated anaplastic large cell lymphoma. https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma, 2022.
  203. American Society of Plastic Surgeons. BIA-ALCL physician resources. https://www.plasticsurgery.org/for-medical-professionals/health-policy/bia-alcl-physician-resources, 2024.
  204. U.S. Food and Drug Administration. Breast implants-certain labeling recommendations to improve patient communication. Guidance for industry and Food and Drug Administration staff. https://www.fda.gov/media/131885/download, 2020.
  205. Dikmans RE, Negenborn VL, Bouman MB, et al. Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial. Lancet Oncol. 18(2):251-258, 2017.
  206. Talwar AA, Lanni MA, Ryan IA, et al. Prepectoral vs. submuscular implant-based breast reconstruction: a matched-pair comparison of outcomes. Plast Reconstr Surg. 153(2):281e-290e, 2024.
  207. Ricci JA, Epstein S, Momoh AO, Lin SJ, Singhal D, Lee BT. A meta-analysis of implant-based breast reconstruction and timing of adjuvant radiation therapy. J Surg Res. 218:108-116, 2018.
  208. Chen JJ, von Eyben R, Gutkin PM, et al. Development of a classification tree to predict implant-based reconstruction failure with or without postmastectomy radiation therapy for breast cancer. Ann Surg Oncol. 28(3):1669-1679, 2021.
  209. U.S. Food and Drug Administration. Breast implants: reports of squamous cell carcinoma and various lymphomas in capsule around implants: FDA safety communication. https://www.fda.gov/medical-devices/safety-communications/breast-implants-reports-squamous-cell-carcinoma-and-various-lymphomas-capsule-around-implants-fda, 2023.
  210. U.S. Food and Drug Administration. Update: reports of squamous cell carcinoma (SCC) in the capsule around breast implants – FDA safety communication. https://www.fda.gov/medical-devices/safety-communications/update-reports-squamous-cell-carcinoma-scc-capsule-around-breast-implants-fda-safety-communication, 2023.
  211. Sarik JR, Bank J, Wu LC, Serletti JM. Superficial inferior epigastric artery: learning curve versus reality. Plast Reconstr Surg. 137(1):1e-6e, 2016.
  212. Zoccali G, Mughal M, Giwa L, Roblin P, Farhadi J. Breast reconstruction with superior gluteal artery perforator free flap: 8 years of experience. J Plast Reconstr Aesthet Surg. 72(10):1623-1631, 2019.
  213. Guzzo HM, Valente SA, Schwarz GS, et al. Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction. Breast Cancer Res Treat. 196(3):657-664, 2022.
  214. Romics L Jr, Chew BK, Weiler-Mithoff E, et al. Ten-year follow-up of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg. 99(6):799-806, 2012.
  215. Mota BS, Riera R, Ricci MD, et al. Nipple- and areola-sparing mastectomy for the treatment of breast cancer. Cochrane Database Syst Rev. 11:CD008932, 2016.
  216. Son JD, Piper M, Hewitt K, et al. Oncological outcomes of total skin-sparing mastectomy for invasive lobular carcinoma of the breast: a 20-year institutional experience. Ann Surg Oncol. 28(5):2555-2560, 2021.
  217. Tang R, Coopey SB, Merrill AL, et al. Positive nipple margins in nipple-sparing mastectomies: rates, management, and oncologic safety. J Am Coll Surg. 222(6):1149-55, 2016.
  218. Smith BL, Tang R, Rai U, et al. Oncologic safety of nipple-sparing mastectomy in women with breast cancer. J Am Coll Surg. 225(3):361-365, 2017.
  219. Wu ZY, Kim HJ, Lee JW, et al. Breast cancer recurrence in the nipple-areola complex after nipple-sparing mastectomy with immediate breast reconstruction for invasive breast cancer. JAMA Surg. 154(11):1030-1037, 2019.
  220. Valero MG, Muhsen S, Moo TA, et al. Increase in utilization of nipple-sparing mastectomy for breast cancer: indications, complications, and oncologic outcomes. Ann Surg Oncol. 27(2):344-351, 2020.
  221. Costeira B, da Silva FB, Oom R, et al. Locoregional recurrence in skin-sparing and nipple-sparing mastectomies. J Surg Oncol. 125(3):352-360, 2022.
  222. Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg. 153(2):123-129, 2018.
  223. Valero MG, Moo T-A, Muhsen S, et al. Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.Br J Surg. 107(10):1307-1312, 2020.
  224. American Cancer Society. What to expect after breast reconstruction surgery. https://www.cancer.org/cancer/breast-cancer/reconstruction-surgery/what-to-expect-after-breast-reconstruction-surgery.html, 2022.
  225. U.S. Department of Labor. Your rights after a mastectomy. https://www.dol.gov/sites/default/files/ebsa/about-ebsa/our-activities/resource-center/publications/your-rights-after-a-mastectomy.pdf, 2018.
  226. Schnipper LE, Smith TJ, Raghavan D, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 30(14):1715-24, 2012.
  227. National Cancer Institute. Breast cancer treatment during pregnancy. http://www.cancer.gov/types/breast/patient/pregnancy-breast-treatment-pdq, 2022.
  228. Litton JK and Theriault RL. Chapter 65: Breast cancer during pregnancy and subsequent pregnancy in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  229. Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 1(8):1145-53, 2015.
  230. Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 31(20):2532-9, 2013.
  231. Johansson ALV, Andersson TM, Hsieh CC, et al. Tumor characteristics and prognosis in women with pregnancy-associated breast cancer. Int J Cancer. 142(7):1343-1354, 2018.
  232. American Cancer Society. Breast Cancer Facts and Figures 2022-2024. Atlanta, GA: American Cancer Society, 2022.
  233. Partridge AH, Goldhirsch A, Gelber S, Gelber RD. Chapter 85: Breast Cancer in Younger Women, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  234. Partridge AH, Niman SM, Ruggeri M, et al. for the International Breast Cancer Study Group; POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 388(18):1645-1656, 2023.
  235. Marklund A, Lundberg FE, Eloranta S, et al. Reproductive outcomes after breast cancer in women with vs without fertility preservation. JAMA Oncol. 7(1):86-91, 2021.
  236. Greer AC, Lanes A, Poorvu PD, et al. The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival. Cancer. 127(20):3872-3880, 2021.
  237. Marklund A, Lekberg T, Hedayati E, et al. Relapse rates and disease-specific mortality following procedures for fertility preservation at time of breast cancer diagnosis. JAMA Oncol. 8(10):1438-1446, 2022.
  238. Wang Y, Tesch ME, Lim C, et al. Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation. Breast Cancer Res Treat. 195(2):201-208, 2022.
  239. Moore HC, Unger JM, Phillips KA, et al. for the POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 372(10):923-32, 2015.
  240. Lambertini M, Boni L, Michelotti A, et al. for the GIM Study Group. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 314(24):2632-40, 2015.
  241. Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2(1):65-73, 2016.
  242. American Cancer Society. Cancer Facts and Figures 2024. Atlanta, GA: American Cancer Society, 2024.
  243. National Cancer Institute. Male breast cancer treatment. http://www.cancer.gov/types/breast/patient/male-breast-treatment-pdq, 2022.
  244. Sarmiento S, McColl M, Musavi L, et al. Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database. Breast Cancer Res Treat. 180(2):471-479, 2020.
  245. American Cancer Society. Can breast cancer in men be found early? https://www.cancer.org/cancer/breast-cancer-in-men/detection-diagnosis-staging/detection.html, 2018.
  246. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast cancer SEER relative survival rates by time since diagnosis, 2000-2020, by sex, all races/ethnicities, all ages, all stages. Accessed on May 6, 2024. https://seer.cancer.gov/explorer/, 2024.
  247. Gradishar WJ and Ruddy KJ. Breast cancer in men. In: Chagpar AB, Hayes DF and Vora SR, eds. UpToDate. Watham, MA, UpToDate, 2023.
  248. Yadav S, Karam D, Bin Riaz I, et al. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer. 126(1):26-36, 2020.
  249. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 60(5): 1079–1084, 1997.
  250. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 99(23):1811-4, 2007.
  251. Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol. 35(20):2240-2250, 2017.
  252. Silvestri V, Leslie L, Barnes DR, et al. Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 6(8):1218-1230, 2020.
  253. Li S, Silvestri V, Leslie G, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 40(14):1529-1541, 2022.
  254. National Cancer Institute. Genetics of breast and gynecologic cancers (PDQ®) – health professional version. https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq, 2023.
  255. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 22(4):735-42, 2004.
  256. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 106(10):1697-701, 2012.
  257. Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 79(8):880-895, 2019.
  258. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 353(5):487-97, 2005.
  259. American Cancer Society. Types and phases of clinical trials. https://www.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-you-need-to-know/phases-of-clinical-trials.html, 2020.
  260. Cancer Research UK. Phases of clinical trials. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/phases-of-clinical-trials#phase0, 2022.
  261. National Cancer Institute. Why participate in a clinical trial. https://www.cancer.gov/research/participate/clinical-trials/why-participate, 2023.
  262. National Comprehensive Cancer Network (NCCN). NCCN: Cancer and COVID-19 vaccination, version 7.0, 2022.
  263. Centers for Disease Control and Prevention. Stay up to date with COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html, 2023.
  264. Charles C, Bardet A, Larive A, et al. Characterization of depressive symptoms trajectories after breast cancer diagnosis in women in France. JAMA Netw Open. 5(4):e225118, 2022.
  265. Schreiber JA, Brockopp DY. Twenty-five years later–what do we know about religion/spirituality and psychological well-being among breast cancer survivors? A systematic review. J Cancer Surviv. 6(1):82-94, 2012.
  266. Krasne M, Ruddy KJ, Poorvu PD, et al. Coping strategies and anxiety in young breast cancer survivors. Support Care Cancer. 30(11):9109-9116, 2022.
  267. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Palliative care. V.2.2023. http://www.nccn.org, 2023.
  268. Johannsen M, Christensen S, Zachariae R, Jensen AB. Socio-demographic, treatment-related, and health behavioral predictors of persistent pain 15 months and 7-9 years after surgery: a nationwide prospective study of women treated for primary breast cancer. Breast Cancer Res Treat. 152(3):645-658, 2015.
  269. Paice JA, Bohlke K, Barton D, et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol 41:914-930, 2022.
  270. Cherny NI and Truong PT. Chapter 79: Brachial plexopathy in patients with breast cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  271. Bruce J, Mazuquin B, Canaway A, et al. for the Prevention of Shoulder Problems Trial (PROSPER) Study Group. Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation. BMJ. 375:e066542, 2021.
  272. Kraus-Tiefenbacher U, Sfintizky A, Welzel G, et al. Factors of influence on acute skin toxicity of breast cancer patients treated with standard external beam radiotherapy (EBRT) after breast conserving surgery (BCS). Radiat Oncol. 7(1):217, 2012.
  273. Allali S, Carton M, Sarrade T, et al. CANTO-RT: Skin toxicities evaluation of a multicentre large prospective cohort of irradiated patients for early-stage breast cancer. Int J Cancer. 151(7):1098-1108, 2022.
  274. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 14(Suppl 4): iv45–iv54, 2012.
  275. Teoh D, Smith TJ, Song M, Spirtos NM. Care after chemotherapy: peripheral neuropathy, cannabis for symptom control, and mindfulness. Am Soc Clin Oncol Educ Book. 469-479, 2018.
  276. Engvall K, Gréen H, Fredriksson M, Åvall-Lundqvist E. Persistent neuropathy among early-stage breast cancer survivors in a population-based cohort. Br J Cancer. 125(3):445-457, 2021.
  277. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. JAMA. 313:2474-83, 2015.
  278. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 313:2456-73, 2015.
  279. Strouse T. Cannabinoids in cancer treatment settings. J Commun Support Oncol. 14:1-5, 2016.
  280. Nugent SM, Morasco BJ, O’Neil ME, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 167(5):319-31, 2017.
  281. Mücke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 3(3):CD012182, 2018.
  282. Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 34(27):3325-45, 2016.
  283. Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between marijuana use and risk of cancer: a systematic review and meta-analysis. JAMA Netw Open. 2(11):e1916318, 2019.
  284. Steele G, Arneson T, Zylla D. A comprehensive review of cannabis in patients with cancer: Availability in the USA, general efficacy, and safety. Curr Oncol Rep 21(1):10, 2019.
  285. American Cancer Society. Developing a pain control plan. https://www.cancer.org/cancer/managing-cancer/side-effects/pain/cancer-pain/developing-a-pain-control-plan.html, 2024.
  286. National Cancer Institute. Pain control: Support for people with cancer. http://www.cancer.gov/publications/patient-education/paincontrol.pdf, 2019.
  287. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Adult cancer pain V.2.2023. http://www.nccn.org/, 2023.
  288. Bower JE, Ganz PA, Irwin MR, et al. Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer. Cancer. 127(8):1334-1344, 2021.
  289. Vaz-Luis I, Di Meglio A, Havas J, et al. Long-term longitudinal patterns of patient-reported fatigue after breast cancer: a group-based trajectory analysis. J Clin Oncol. 40(19):2148-2162, 2022.
  290. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 11:CD006145, 2012.
  291. Hayes SC, Rye S, Disipio T, et al. Exercise for health: a randomized, controlled trial evaluating the impact of a pragmatic, translational exercise intervention on the quality of life, function and treatment-related side effects following breast cancer. Breast Cancer Res Treat. 137(1):175-86, 2013.
  292. Bolam KA, Mijwel S, Rundqvist H, Wengström Y. Two-year follow-up of the OptiTrain randomised controlled exercise trial. Breast Cancer Res Treat. 175(3):637-648, 2019.
  293. Bower JE, Garet D, Sternlieb B, et al. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial. Cancer. 118(15):3766-75, 2012.
  294. Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 1:CD010802, 2017.
  295. Danhauer SC, Addington EL, Cohen L, et al. Yoga for symptom management in oncology: A review of the evidence base and future directions for research. Cancer. 125(12):1979-1989, 2019.
  296. Molassiotis A, Bardy J, Finnegan-John J, et al. Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial. J Clin Oncol. 30(36):4470-6, 2012.
  297. Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 30(30):3687-96, 2012.
  298. Montgomery GH, David D, Kangas M, et al. Randomized controlled trial of a cognitive-behavioral therapy plus hypnosis intervention to control fatigue in patients undergoing radiotherapy for breast cancer. J Clin Oncol. 32(6):557-63, 2014.
  299. Lengacher CA, Reich RR, Paterson CL, et al. Examination of broad symptom improvement resulting from mindfulness-based stress reduction in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 34(24):2827-34, 2016.
  300. Abrahams HJG, Gielissen MFM, Donders RRT, et al. The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial. Cancer. 123(19):3825-3834, 2017.
  301. Bower JE, Partridge AH, Wolff AC, et al. Targeting depressive symptoms in younger breast cancer survivors: the Pathways to Wellness randomized controlled trial of mindfulness meditation and survivorship education. J Clin Oncol. 39(31):3473-3484, 2021.
  302. Mustian KM, Sprod LK, Janelsins M, et al. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol. 31(26): 3233-41, 2013.
  303. Lengacher CA, Reich RR, Paterson CL, et al. The effects of mindfulness-based stress reduction on objective and subjective sleep parameters in women with breast cancer: a randomized controlled trial. Psychooncology. 24(4):424-32, 2015.
  304. Garland SN, Carlson LE, Stephens AJ, Antle MC, Samuels C, Campbell TS. Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial. J Clin Oncol. 32(5):449-57, 2014.
  305. Roscoe JA, Garland SN, Heckler CE, et al. Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. J Clin Oncol. 33(2):165-71, 2015.
  306. Irwin MR, Olmstead R, Carrillo C, et al. Tai chi chih compared with cognitive behavioral therapy for the treatment of insomnia in survivors of breast cancer: a randomized, partially blinded, noninferiority trial. J Clin Oncol. 35(23):2656-2665, 2017.
  307. Zachariae R, Amidi A, Damholdt MF, et al. Internet-delivered cognitive-behavioral therapy for insomnia in breast cancer survivors: a randomized controlled trial. J Natl Cancer Inst. 110(8):880-887, 2018.
  308. Kreutz C, Schmidt ME, Steindorf K. Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis. Breast Cancer Res Treat. 176(1):1-15, 2019.
  309. Garland SN, Xie SX, DuHamel K, et al. Acupuncture versus cognitive behavioral therapy for insomnia in cancer survivors: a randomized clinical trial. J Natl Cancer Inst. 111(12):1323-1331, 2019.
  310. Lu W, Cui Y, Chen X, et al. Changes in quality of life among breast cancer patients three years post-diagnosis. Breast Cancer Res Treat. 114(2):357-69, 2009.
  311. Tran TXM, Jung SY, Lee EG, et al. Long-term trajectory of postoperative health-related quality of life in young breast cancer patients: a 15-year follow-up study. J Cancer Surviv. 17(5):1416-1426, 2023.
  312. Shapiro SL, Lopez AM, Schwartz GE, et al. Quality of life and breast cancer: relationship to psychosocial variables. J Clin Psychol. 57(4):501-19, 2001.
  313. Horgan O, Holcombe C, Salmon P. Experiencing positive change after a diagnosis of breast cancer: a grounded theory analysis. Psychooncology. 20(10):1116-25, 2011.
  314. Perkins EA, Small BJ, Balducci L, Extermann M, Robb C, Haley WE. Individual differences in well-being in older breast cancer survivors. Crit Rev Oncol Hematol. 62(1):74-83, 2007.
  315. Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial. J Clin Oncol. 39(14):1518-1530, 2021.
  316. Gnant M, Dueck AC, Frantal S, et al. for the PALLAS groups and investigators. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 40(3):282-293, 2022.
  317. Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline. J Clin Oncol. 42(5):584-604, 2024.
  318. Nahabedian M. Overview of breast reconstruction. In: UpToDate (Chagpar AB, Colwell AS and Collins KA, eds.). Waltham, MA: UpToDate, 2024.
  319. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 390(12):1080-1091, 2024.
  320. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 373(21):2005-14, 2015.
  321. Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 385(25):2336-2347, 2021.
  322. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 379(2):111-121, 2018.
  323. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 379(2):111-121, 2018.
  324. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 105(10):701-10, 2013.
  325. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J Natl Cancer Inst. 109(4):djw256, 2017.
  326. Rakovitch E, Sutradhar R, Nofech-Mozes S, et al. 21-gene assay and breast cancer mortality in ductal carcinoma in situ. J Natl Cancer Inst. 113(5):572-579, 2021.
  327. Rakovitch E, Parpia S, Koch A, et al. DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS. Breast Cancer Res Treat. 188(1):133-139, 2021.
  328. Piccart M, van ‘t Veer LJ, Poncet C, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 22(4):476-488, 2021.
  329. Seth I, Nimish S, Bulloch G, Rozen W, Hunter-Smith DJ. Systematic review of Breast-Q: a tool to evaluate post-mastectomy breast reconstruction. Breast Cancer (Dove Med Press). 13:711-724, 2021.
  330. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer screening and diagnosis, Version 2.2024. http://www.nccn.org, 2024.
  331. Hurvitz SA, Martin M, Press MF, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+/HER2- breast cancer. 26(3):566-580, 2020.
  332. U.S. Food and Drug Administration (FDA). Kisqali labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092s018lbl.pdf, 2024.
  333. American Cancer Society. Breast Cancer Facts and Figures 2024-2025. Atlanta, GA: American Cancer Society, 2024.
  334. Centers for Disease Control and Prevention. Cancer and COVID-19. https://www.cdc.gov/cancer/initiatives/covid-19.html, 2024.
  335. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Survivorship. V.1.2024. http://www.nccn.org, 2024.

Updated 10/10/24  

TOOLS & RESOURCES

PDF

Fact Sheet

Support After a Breast Cancer Diagnosis